Endometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages

DelveInsight's, "Endometriosis Pain Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Endometriosis Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Endometriosis Pain Pipeline Insight 2023 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Endometriosis Pain pipeline landscape is provided which includes the disease overview and Endometriosis Pain treatment guidelines. The assessment part of the report embraces, in depth Endometriosis Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Endometriosis Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key highlights of the Endometriosis Pain Pipeline Analysis Report
• The report provides detailed insights about companies that are developing therapies in the Endometriosis Pain Market.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometriosis Pain treatment.
• Endometriosis Pain companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Endometriosis Pain Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometriosis Pain market.

The report is built using data and information traced from the researcher proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample Report @ https://www.delveinsight.com/sample-request/endometriosis-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Endometriosis Pain Overview
Endometriosis is a chronic and debilitating condition affecting ∼10% of women. Endometriosis is characterized by infertility and chronic pelvic pain, yet treatment options remain limited. In many respects this is related to an underlying lack of knowledge of the etiology and mechanisms contributing to endometriosis-induced pain.

Endometriosis Pain Pipeline Therapeutic Analysis
There are approx. 5+ key companies which are developing the therapies for Endometriosis Pain. The companies which have their Endometriosis Pain drug candidates in the most advanced stage, i.e. phase III include, ObsEva.

Endometriosis Pain Emerging Drugs

Quinagolide: Ferring Pharmaceuticals
Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. Hyperprolalctinaemia is associated with gonadal dysfunction, including infertility and reduced, as well as long-term complications such as osteoporosis 1. Newer dopamine receptor agonists such as quinagolide and Cabergoline are shown to effectively inhibit prolactin secretion with improved efficacy over Bromocriptine. These drugs are effective in patients who are intolerant or resistant to Bromocriptine. Quinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the (-) enantiomer. It is typically present in the hydrochloride salt form and is marketed as oral tablets under the brand name Norprolac contained as a racemate. Quinagolide is currently available in several countries including Canada, but not approved for treatment in the United States. The drug is currently in Phase II stage of clinical trial evaluation to treat Endometriosis-related Pain.

Linzagolix: ObsEva
Linzagolix is a novel, orally administered GnRH receptor antagonist that potentially provides effective management of endometriosis-associated pain while mitigating bone mineral density loss and other adverse effects typically associated with currently approved treatments. Unlike marketed GnRH agonists, Linzagolix has the potential to be administered orally once a day, with symptoms relieved within days, while potentially mitigating the initial worsening of symptoms often associated with GnRH agonist treatments. Linzagolix has the potential to dose-dependently lower estradiol levels hence maintaining such levels within an optimal range to mitigate patient bone mineral density loss. Linzagolix has the potential to allow patients to receive the relief needed to live normal lives again and enhance their quality of life with fewer side effects and complications requiring doctor's visits or surgery.

Endometriosis Pain Pipeline Companies
• Ferring Pharmaceuticals
• ObsEva SA
• Myovant Sciences
• Hope Medicine (Nanjing) Co., Ltd
• TiumBio Co., Ltd.
• Mitsubishi Tanabe Pharma, and Several Others

Endometriosis Pain Pipeline Phases
DelveInsight's report covers around 5+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Endometriosis Pain Pipeline Report Highlights
• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Endometriosis Pain.
• In the coming years, the Endometriosis Pain market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Endometriosis Pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Endometriosis Pain treatment market. Several potential therapies for Endometriosis Pain are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Endometriosis Pain market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Endometriosis Pain) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Request Sample Report @ https://www.delveinsight.com/sample-request/endometriosis-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of content
1. Introduction
2. Executive Summary
3. Endometriosis Pain: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Endometriosis Pain - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Linzagolix: ObsEva
9. Mid Stage Products (Phase II)
10. Quinagolide: Ferring Pharmaceuticals
11. Early Stage Products (Phase I)
12. Drug name: Company name
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Endometriosis Pain Key Companies
17. Endometriosis Pain Key Products
18. Endometriosis Pain- Unmet Needs
19. Endometriosis Pain- Market Drivers and Barriers
20. Endometriosis Pain- Future Perspectives and Conclusion
21. Endometriosis Pain Analyst Views
22. Endometriosis Pain Key Companies
23. Appendix

Got Queries? Find out the related information on Endometriosis Pain Mergers and acquisitions, Endometriosis Pain Licensing Activities @ Endometriosis Pain Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/endometriosis-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.